Back to search

Switzerland· 68026001

Veklury, Pulver für Konzentrat zur Herstellung einer Infusionslösung

A remdesivir product containing remdesivirum, registered in Switzerland by Gilead Sciences Switzerland Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AB16

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVeklury, Pulver für Konzentrat zur He…ATCJ05AB16REGISTER NO.68026001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Remdesivir is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AB16 (remdesivir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Remdesivir · ATC J05AB16

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of remdesivir costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), so markets compare like for like.

  • Switzerland: $622.55 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Remdesivir · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • CH Switzerland$622.55
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
remdesivirum
Manufacturer
Gilead Sciences Switzerland Sàrl
Country
Switzerland (CH)
ATC code
J05AB16
ATC class
Remdesivir
Defined daily dose
0.12 g, P
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680680260012
    Durchstf 1 Stk
    CHF 430.25

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

252 interactions on record for remdesivir.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Remdesivir · interactions on record

252 records

  • 2 severe
  • 250 moderate

Most severe, free to view

  • ClotrimazoleA01AB18moderate
  • Chenodeoxycholic acidA05AA01moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ed7088af-0763-42b3-b92a-c224ddfd5c80
GET /v1/drugs/ed7088af-0763-42b3-b92a-c224ddfd5c80?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "remdesivirum 100 mg",
  "valid_from": "2023-12-01",
  "limitations": "[{\"description\":\"VEKLURY als antivirale Monotherapie wird bei einer Behandlung einer bestätigten Covid-19 Infektion (Symptomatik und positiver Erregernachweis Antigen/PCR) in folgenden Fällen vergütet:<br>\\n<br>\\n•\\tErwachsenen und pädiatrischen Patienten (im Alter von mindestens 4 Wochen und mit einem Körpergewicht von mindestens 3 kg) mit einer Pneumonie, die eine zusätzliche Sauerstoffzufuhr erfordert (Low- oder High-Flow-Sauerstoff oder andere nicht-invasive Beatmung zu Beginn der Behandlung)<br>\\n•\\tzur Frühbehandlung (innerhalb von 5 Tagen nach Symptombeginn, ausser bei immunsupprimierten Personen) bei Erwachsenen und pädiatrischen Patienten (mit einem Körpergewicht von mindestens 40 kg), die keine zusätzliche Sauerstoffzufuhr oder Hospitalisierung aufgrund von COVID-19 benötigen und bei welchen gemäss der aktuell gültigen Richtlinie der Schweizerischen Gesellschaft für Infektiologie (SSI) (https://www.sginf.ch/guidelines/guidelines-overview.html) ein erhöhtes Risiko für einen schweren COVID-19-Verlauf besteht.<br>\\n<br>\\nFür die frühzeitige ambulante Behandlung von Hochrisikopatienten, die keine zusätzliche Sauerstoffzufuhr oder Hospitalisierung aufgrund von COVID-19 benötigen, wird für eine Erkrankung maximal eine Dosierung von 400mg während 3 Tagen vergütet (Tag 1: 200mg, Tag 2: 100mg: Tag 3: 100mg).<br>\\n<br>\\nDie ambulante Behandlung muss durch entsprechend spezialisierte Zentren oder Universitätsspitäler (https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Arzneimittel/Referenzdokumente-zur-Spezialitaetenliste.html) eingeleitet werden.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21439.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2026-12-31\"}]",
  "galenic_form": "Trockensub 100 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-09-01",
  "self_retention_pct": 10
}

See everything about remdesivir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.